Dare Bioscience Investor Presentation Deck

XACIATO: Overview ➤XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. ➤ This marks the first FDA-approved product in Daré's portfolio of potential first-in-category development candidates. ➤XACIATO is expected to be available commercially in the U.S. in 4Q 2022. Supply to support commercial launch expected earliest summer 2022. QIDP, Fast Track and Priority Review Designations NDA Approved December 7, 2021 18

View entire presentation